These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 6117927

  • 1. [Abnormalities of catecholamine metabolism in Parkinson's disease (author's transl)].
    Nagatsu T.
    Tanpakushitsu Kakusan Koso; 1981 Aug; 26(11):1781-8. PubMed ID: 6117927
    [No Abstract] [Full Text] [Related]

  • 2. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O.
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract] [Full Text] [Related]

  • 3. [Parkinson's disease].
    Nagatsu T.
    Tanpakushitsu Kakusan Koso; 1984 Dec; 29(14):1801-14. PubMed ID: 6152497
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Biochemical bases of Parkinson disease].
    Colucci d'Amato C, Puccini A, Cristillo A, Vizioli R.
    Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
    [No Abstract] [Full Text] [Related]

  • 6. Experimentally induced parkinsonism.
    Poirier LJ, Sourkes TL.
    Res Publ Assoc Res Nerv Ment Dis; 1972 Oct; 50():416-33. PubMed ID: 4403656
    [No Abstract] [Full Text] [Related]

  • 7. Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea.
    McGeer PL, McGeer EG.
    J Neurochem; 1976 Jan; 26(1):65-76. PubMed ID: 3629
    [No Abstract] [Full Text] [Related]

  • 8. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
    Sajadi A, Bauer M, Thöny B, Aebischer P.
    J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
    [Abstract] [Full Text] [Related]

  • 9. Biochemical aspects of Parkinson's disease.
    Nagatsu T.
    Adv Neurol; 1993 Jun; 60():165-74. PubMed ID: 8093575
    [No Abstract] [Full Text] [Related]

  • 10. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN.
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [Abstract] [Full Text] [Related]

  • 11. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS, Starr MS.
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [Abstract] [Full Text] [Related]

  • 12. Catecholamine-metabolizing enzyme activity in the nigrostriatal system.
    Francis A, Whittemore R, Jeffery DR, Pearce LB, Roth JA.
    Biochem Pharmacol; 1987 Jul 01; 36(13):2229-31. PubMed ID: 3111478
    [No Abstract] [Full Text] [Related]

  • 13. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
    Darmopil S, Muñetón-Gómez VC, de Ceballos ML, Bernson M, Moratalla R.
    Eur J Neurosci; 2008 Feb 01; 27(3):580-92. PubMed ID: 18279311
    [Abstract] [Full Text] [Related]

  • 14. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA, Weiner N.
    J Pharmacol Exp Ther; 1993 Dec 01; 267(3):1105-11. PubMed ID: 8263772
    [Abstract] [Full Text] [Related]

  • 15. Biochemical pathophysiology of Parkinson's disease.
    Hornykiewicz O, Kish SJ.
    Adv Neurol; 1987 Dec 01; 45():19-34. PubMed ID: 2881444
    [No Abstract] [Full Text] [Related]

  • 16. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L, Garris BL, Garris DR, Lau YS.
    Neuroscience; 2006 Jun 19; 140(1):67-76. PubMed ID: 16533572
    [Abstract] [Full Text] [Related]

  • 17. [L-dopa-resistant Parkinson's disease with cerebral atrophy: striato-nigral degeneration?].
    Dell'Aria V, Ciannella L, Melone MA.
    Acta Neurol Quad (Napoli); 1981 Jun 19; 42():212-5. PubMed ID: 7270052
    [No Abstract] [Full Text] [Related]

  • 18. Enzymatic stimulation and enzymatic inhibition in Parkinson's disease.
    Nagatsu T.
    Acta Neurol Scand Suppl; 1993 Jun 19; 146():14-7. PubMed ID: 8101411
    [Abstract] [Full Text] [Related]

  • 19. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats].
    Wang S, Qi XJ, Han D.
    Zhongguo Zhen Jiu; 2009 May 19; 29(5):391-4. PubMed ID: 19489498
    [Abstract] [Full Text] [Related]

  • 20. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.
    Elsworth JD, Roth RH.
    Exp Neurol; 1997 Mar 19; 144(1):4-9. PubMed ID: 9126143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.